½ÃÀ庸°í¼­
»óǰÄÚµå
1599623

¿©¼º °Ç°­ ½ÃÀå : ¿¬·É, À¯Åë ä³Î, ¿ëµµº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Women¢¥s Health Market by Age (13-17 Years, 18-35 Years, 36 Years & Above), Distribution Channel (Hospital, Online, Retail), Application - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 198 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¿©¼º °Ç°­ ½ÃÀåÀº 2023³â 432¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç 2024³â¿¡´Â 469¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¬Æò±Õ 8.97% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 789¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿©¼º °Ç°­ ½ÃÀå¿¡´Â ¿©¼ºÀÇ Àü »ý¾Ö¿¡ °ÉÃÄ ¿©¼º ƯÀ¯ÀÇ °Ç°­ ¿ä±¸¸¦ ÃæÁ·½Ã۱â À§ÇÑ ´Ù¾çÇÑ Á¦Ç°°ú ¼­ºñ½º°¡ Æ÷ÇԵ˴ϴÙ. ÀÌ ºÐ¾ß¿¡´Â »ý½Ä °Ç°­, °»³â±â, °ñ´Ù°øÁõ, ¿µ¾ç ºÎÁ· µîÀÇ ºÐ¾ß¸¦ ´ë»óÀ¸·Î ÇÏ´Â ÀǾàǰ, ÀÇ·á±â±â, À£´Ï½º Á¦Ç°, Áø´Ü, ÀüÀÎÀû °Ç°­ ¼­ºñ½º µîÀÌ Æ÷ÇԵ˴ϴÙ. ¿©¼º °Ç°­ÀÇ Çʿ伺Àº À¯¹æ¾Ï, ºÎÀΰú Áúȯ, Á¤½Å°Ç°­°ú °°Àº »óÅ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¶Ñ·ÇÇÑ »ý¹°ÇÐÀû, È£¸£¸óÇÐÀû ¿äÀο¡ »Ñ¸®¸¦ µÎ°í ÀÖÀ¸¸ç, ÀÌ·Î ÀÎÇØ Àü¹®ÀûÀÎ Á¦Ç° ¹× Ä¡·á°¡ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀº 10´ë ¼Ò³à, ÀþÀº ¿©¼º, ÀÓ»êºÎ, ³ëÀÎÀ» Æ÷ÇÔÇÑ ±¤¹üÀ§ÇÑ ÃÖÁ¾»ç¿ëÀÚÃþÀ» ´ë»óÀ¸·Î ÇÏ´Â ÀÇ·á ½Ã¼³, ÀçÅà Áø·á, Àü¹® Ŭ¸®´Ð¿¡¼­ÀÇ Àû¿ë¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡, ÀÇ·á¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ÀÇ·á ¼­ºñ½º Á¦°øÀÇ ±â¼ú ¹ßÀü µîÀÌ ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 432¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 469¾ï 9,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 789¾ï ´Þ·¯
CAGR(%) 8.97%

¿©¼ºÀÇ °í·ÉÈ­¿Í ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¸ÂÃãÇü ÀÇ·á ¹× ¿ø°ÝÀÇ·á Ç÷§Æû°ú °°Àº µðÁöÅÐ °Ç°­ ¼Ö·ç¼Ç¿¡ Å« ºñÁî´Ï½º ±âȸ°¡ ÀÖ½À´Ï´Ù. ±â¾÷µéÀº AI ±â¹Ý Áø´Ü ¹× ¿þ¾î·¯ºí °Ç°­ ÃßÀû±â¿¡ ÅõÀÚÇÔÀ¸·Î½á ÀÌ·¯ÇÑ Ãß¼¼¸¦ Ȱ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÚ¿¬ÀûÀ̰í À¯±âÀûÀÎ °Ç°­ ¼Ö·ç¼ÇÀ¸·ÎÀÇ ÀüȯÀº Çõ½ÅÀ» À§ÇÑ ¼ºÀå °ø°£À» Á¦°øÇÕ´Ï´Ù. ±×·¯³ª ½ÃÀåÀº ¾ö°ÝÇÑ ±ÔÁ¦ ȯ°æ, ³ôÀº R&D ºñ¿ë, ÀÇ·á ¼­ºñ½º Á¢±Ù¼ºÀ» Á¦ÇÑÇÏ´Â »çȸ°æÁ¦Àû °ÝÂ÷ µîÀÇ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù.

±â¼ú Çõ½ÅÀÇ °¡Àå ÁÁÀº ºÐ¾ß´Â ƯÈ÷ È£¸£¸ó ¹× »ý½Ä±â Áúȯ¿¡ ´ëÇÑ °³ÀÎÈ­µÈ ºñħ½ÀÀû Áø´Ü µµ±¸ÀÇ °³¹ß°ú ȯÀÚ Âü¿©¿Í Ä¡·áÀÇ ¿¬¼Ó¼ºÀ» ³ôÀ̱â À§ÇÑ µðÁöÅÐ °Ç°­ ¼Ö·ç¼ÇÀÇ ÅëÇÕÀÔ´Ï´Ù. ½ÃÀåÀº ¿ªµ¿ÀûÀ̸ç, ¼ÒºñÀÚ ¼±È£µµ º¯È­¿Í ±ÔÁ¦ º¯È­¿¡ µû¶ó Áö¼ÓÀûÀÎ ÀûÀÀ°ú ¿¬±¸°¡ ÇÊ¿äÇÑ ¿ªµ¿ÀûÀÎ ½ÃÀåÀÔ´Ï´Ù. ±â¾÷Àº Çõ½ÅÀ» ÃËÁøÇÏ°í ½ÃÀå ħÅõ·ÂÀ» ³ôÀ̱â À§ÇØ ÆÄÆ®³Ê½Ê°ú Çù¾÷¿¡ ÁýÁßÇØ¾ß ÇÕ´Ï´Ù. ¶ÇÇÑ, ¿©¼ºµéÀÇ °Ç°­ ¹®ÇØ·ÂÀ» Çâ»ó½Ã۰í, Áö½Ä °ÝÂ÷¸¦ ÇØ¼ÒÇϰí, Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ µµ¿òÀ» ÁÖ´Â °Íµµ Áß¿äÇÕ´Ï´Ù. Áö¼Ó°¡´ÉÇÑ ¼ºÀåÀ» À§ÇØ ±â¾÷Àº ¿©¼º °Ç°­ ¼Ö·ç¼ÇÀÇ Á¢±Ù¼º ¹× Á¢±Ù¼ºÀ» Àû±ØÀûÀ¸·Î °³¼±ÇÏ¿© ´Ù¾çÇÑ »çȸ°æÁ¦Àû ±×·ì¿¡ ´ëÀÀÇÒ ¼ö ÀÖµµ·Ï ÇØ¾ß ÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ¿©¼º °Ç°­ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

¿©¼º °Ç°­ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¿©¼ºÀÇ È£¸£¸ó ºÒ±ÕÇü°ú ¸¸¼ºÁúȯ Áõ°¡
    • ½´ÆÛǪµå Æ®·»µå Áõ°¡¿Í ¿©¼º¿ë Á¾ÇÕºñŸ¹ÎÀÇ º¸±Þ·ü Áõ°¡
    • ÀÚ¿¬½Äǰ°ú ½Ä¹°¼º °Ç°­º¸Á¶½Äǰ¿¡ ´ëÇÑ ¿©¼ºµéÀÇ ¼±È£µµ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÀÓ»ó Ä¡·áºñ Æøµî
  • ½ÃÀå ±âȸ
    • È£¸£¸ó Àå¾Ö Ä¡·áÁ¦ °³¹ßÀ» À§ÇÑ ¿¬±¸°³¹ß Ȱµ¿ Ȱ¼ºÈ­
    • ¿©¼º °Ç°­ ÁõÁøÀ» À§ÇØ ¼¼°è °¢±¹ Á¤ºÎ°¡ ½ÃÇàÇÏ´Â ¿©¼º ¿ì´ë Á¤Ã¥
  • ½ÃÀå °úÁ¦
    • ¾à¹° ¼·Ãë¿¡ µû¸¥ ºÎÀÛ¿ë

Porter's Five Forces : ¿©¼º °Ç°­ ½ÃÀå °ø·«À» À§ÇÑ Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲÀÇ °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¿©¼º °Ç°­ ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¿©¼º °Ç°­ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ¿©¼º °Ç°­ ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆÄ¾Ç

¿©¼º °Ç°­ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ¿©¼º °Ç°­ ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¿©¼º °Ç°­ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¿©¼º °Ç°­ ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× Ãßõ ¿©¼º °Ç°­ ½ÃÀå ¼º°øÀÇ ±æÀ» ±×¸³´Ï´Ù.

¿©¼º °Ç°­ ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ÇâÈÄ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ¿©¼º °Ç°­ ½ÃÀå : ¿¬·Éº°

  • 13-17¼¼
  • 18-35¼¼
  • 36¼¼ ÀÌ»ó

Á¦7Àå ¿©¼º °Ç°­ ½ÃÀå : À¯Åë ä³Îº°

  • º´¿ø
  • ¿Â¶óÀÎ
  • ¼Ò¸Å

Á¦8Àå ¿©¼º °Ç°­ ½ÃÀå : ¿ëµµº°

  • ÇÇÀÓ¾à
  • Àڱ󻸷Áõ°ú ÀڱñÙÁ¾
  • È£¸£¸ó¼º ºÒÀÓ
  • Æó°æ
  • ´Ù³¶¼º³­¼ÒÁõÈıº
  • Æó°æÈÄ °ñ´Ù°øÁõ

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ¿©¼º °Ç°­ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¿©¼º °Ç°­ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¿©¼º °Ç°­ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦12Àå °æÀï »óȲ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Abbott Laboratories
  • AbbVie Inc.
  • Agile Therapeutics, Inc.
  • Alembic Pharmaceuticals Ltd.
  • Amgen Inc.
  • Apothecus Pharmaceutical Corp.
  • Ar-Ex Laboratories Pvt. Ltd.
  • AstraZeneca PLC
  • AVA Sciences by FemTec Health Inc.
  • Bayer AG
  • Bharat Serums and Vaccines Ltd.
  • Boston Imaging
  • Cipla Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Ferring B.V.
  • GE HealthCare
  • Gennev, Inc. by Unified Women's Healthcare
  • Hologic, Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Mankind Pharma Ltd.
  • Mira by Quanovate Tech Inc.
  • Mylan N.V. by Viatris
  • Novartis AG
  • Pfizer, Inc.
  • Pregna International Ltd.
  • Quest Diagnostics Incorporated
  • Serum Institute Of India Ltd.
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Siemens AG
  • Sysmex Asia Pacific Pte Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • The Himalaya Drug Company
  • TherapeuticsMD, Inc.
  • Thermo Fisher Scientific Inc.
  • Torrent Pharmaceuticals Ltd.
  • Triglobal Lifesciences(opc) Pvt. Ltd.
ksm 24.12.04

The Women's Health Market was valued at USD 43.23 billion in 2023, expected to reach USD 46.99 billion in 2024, and is projected to grow at a CAGR of 8.97%, to USD 78.90 billion by 2030.

The women's health market encompasses a broad range of products and services aimed at addressing the unique health needs of women throughout their life stages. This sector includes pharmaceuticals, medical devices, wellness products, diagnostics, and holistic health services targeting areas such as reproductive health, menopause, osteoporosis, and nutritional deficiencies. The necessity of women's health is rooted in the distinct biological and hormonal factors influencing conditions like breast cancer, gynecological disorders, and mental health, thereby necessitating specialized products and treatments. The market is driven by applications in healthcare facilities, homecare, and specialized clinics, catering to an expansive end-users demographic, including teenage girls, young women, pregnant women, and seniors. Key factors influencing market growth include the rising incidence of chronic conditions, increasing healthcare awareness, and technological advancements in healthcare delivery.

KEY MARKET STATISTICS
Base Year [2023] USD 43.23 billion
Estimated Year [2024] USD 46.99 billion
Forecast Year [2030] USD 78.90 billion
CAGR (%) 8.97%

With the aging female population and increasing emphasis on preventive healthcare, significant opportunities lie in personalized medicine and digital health solutions like telemedicine platforms. Companies can capitalize on these trends by investing in AI-driven diagnostics and wearable health trackers. Additionally, the shift towards natural and organic health solutions offers a growing space for innovation. However, the market faces challenges such as stringent regulatory environments, high research and development costs, and socio-economic disparities limiting access to healthcare.

The best areas for innovation include the development of personalized, non-invasive diagnostic tools, especially for hormonal and reproductive disorders, and the integration of digital health solutions to enhance patient engagement and care continuity. The market is dynamic, with shifting consumer preferences and regulatory changes, necessitating continuous adaptation and research. Companies should focus on partnerships and collaborations to foster innovation and improve market penetration. It's also critical to enhance health literacy among women, bridging the knowledge gap to aid informed decision-making. For sustained growth, companies should proactively address the accessibility and affordability of women's health solutions, ensuring they cater to diverse socio-economic groups.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Women's Health Market

The Women's Health Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing cases of hormonal imbalances and chronic diseases in women
    • Rising trend of superfood and increasing availability of multivitamins for women
    • Inclination of women towards natural and plant based health supplements
  • Market Restraints
    • High cost of clinical treatments
  • Market Opportunities
    • Rising R&D activities for drug development to treat the hormonal disorders
    • Favorable policies initiated by governments worlwide to improve women's health
  • Market Challenges
    • Side-effects associated with consumption of drugs

Porter's Five Forces: A Strategic Tool for Navigating the Women's Health Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Women's Health Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Women's Health Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Women's Health Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Women's Health Market

A detailed market share analysis in the Women's Health Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Women's Health Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Women's Health Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Women's Health Market

A strategic analysis of the Women's Health Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Women's Health Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Agile Therapeutics, Inc., Alembic Pharmaceuticals Ltd., Amgen Inc., Apothecus Pharmaceutical Corp., Ar-Ex Laboratories Pvt. Ltd., AstraZeneca PLC, AVA Sciences by FemTec Health Inc., Bayer AG, Bharat Serums and Vaccines Ltd., Boston Imaging, Cipla Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Ferring B.V., GE HealthCare, Gennev, Inc. by Unified Women's Healthcare, Hologic, Inc., Johnson & Johnson Services, Inc., Lupin Limited, Mankind Pharma Ltd., Mira by Quanovate Tech Inc., Mylan N.V. by Viatris, Novartis AG, Pfizer, Inc., Pregna International Ltd., Quest Diagnostics Incorporated, Serum Institute Of India Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens AG, Sysmex Asia Pacific Pte Ltd., Teva Pharmaceutical Industries Ltd., The Himalaya Drug Company, TherapeuticsMD, Inc., Thermo Fisher Scientific Inc., Torrent Pharmaceuticals Ltd., and Triglobal Lifesciences (opc) Pvt. Ltd..

Market Segmentation & Coverage

This research report categorizes the Women's Health Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Age, market is studied across 13-17 Years, 18-35 Years, and 36 Years & Above.
  • Based on Distribution Channel, market is studied across Hospital, Online, and Retail.
  • Based on Application, market is studied across Contraceptives, Endometriosis & Uterine Fibroids, Hormonal Infertility, Menopause, Polycystic Ovary Syndrome, and Postmenopausal Osteoporosis.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing cases of hormonal imbalances and chronic diseases in women
      • 5.1.1.2. Rising trend of superfood and increasing availability of multivitamins for women
      • 5.1.1.3. Inclination of women towards natural and plant based health supplements
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of clinical treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising R&D activities for drug development to treat the hormonal disorders
      • 5.1.3.2. Favorable policies initiated by governments worlwide to improve women's health
    • 5.1.4. Challenges
      • 5.1.4.1. Side-effects associated with consumption of drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Women's Health Market, by Age

  • 6.1. Introduction
  • 6.2. 13-17 Years
  • 6.3. 18-35 Years
  • 6.4. 36 Years & Above

7. Women's Health Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital
  • 7.3. Online
  • 7.4. Retail

8. Women's Health Market, by Application

  • 8.1. Introduction
  • 8.2. Contraceptives
  • 8.3. Endometriosis & Uterine Fibroids
  • 8.4. Hormonal Infertility
  • 8.5. Menopause
  • 8.6. Polycystic Ovary Syndrome
  • 8.7. Postmenopausal Osteoporosis

9. Americas Women's Health Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Women's Health Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Women's Health Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Women's health startup Iron Health launches with $4.5M.
    • 12.3.2. Onsite Women's Health and Volpara Health Announce National Partnership.
    • 12.3.3. Kiran Mazumdar Shaw invests in women's health platform Gytree.com.
    • 12.3.4. Bharat Serums and Vaccines will acquire Firstline Pharma, Genomicks to enhance its presence in women's health segment.
    • 12.3.5. Unified Women's Healthcare acquires menopause care platform Gennev.
    • 12.3.6. Carlyle and PAI on women's healthcare.
    • 12.3.7. Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis.
    • 12.3.8. FemTec Health Acquires Nutrimedy, Adds Personalized Nutrition to Women's Health Suite.
    • 12.3.9. HempStreet announces strategic partnership with Gynica.
    • 12.3.10. Organon is going to significantly expand the production of long-acting contraception in the Netherlands.
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Agile Therapeutics, Inc.
  • 4. Alembic Pharmaceuticals Ltd.
  • 5. Amgen Inc.
  • 6. Apothecus Pharmaceutical Corp.
  • 7. Ar-Ex Laboratories Pvt. Ltd.
  • 8. AstraZeneca PLC
  • 9. AVA Sciences by FemTec Health Inc.
  • 10. Bayer AG
  • 11. Bharat Serums and Vaccines Ltd.
  • 12. Boston Imaging
  • 13. Cipla Limited
  • 14. Eli Lilly and Company
  • 15. F. Hoffmann-La Roche Ltd.
  • 16. Ferring B.V.
  • 17. GE HealthCare
  • 18. Gennev, Inc. by Unified Women's Healthcare
  • 19. Hologic, Inc.
  • 20. Johnson & Johnson Services, Inc.
  • 21. Lupin Limited
  • 22. Mankind Pharma Ltd.
  • 23. Mira by Quanovate Tech Inc.
  • 24. Mylan N.V. by Viatris
  • 25. Novartis AG
  • 26. Pfizer, Inc.
  • 27. Pregna International Ltd.
  • 28. Quest Diagnostics Incorporated
  • 29. Serum Institute Of India Ltd.
  • 30. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 31. Siemens AG
  • 32. Sysmex Asia Pacific Pte Ltd.
  • 33. Teva Pharmaceutical Industries Ltd.
  • 34. The Himalaya Drug Company
  • 35. TherapeuticsMD, Inc.
  • 36. Thermo Fisher Scientific Inc.
  • 37. Torrent Pharmaceuticals Ltd.
  • 38. Triglobal Lifesciences (opc) Pvt. Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦